SNORD35A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Target Name: SNORD35A

NCBI ID: G26816

SNORD35A

Other Name(s): Small nucleolar RNA, C/D box 35A | U35 | RNU35 | RNU35A | small nucleolar RNA, C/D box 35A

SNORD35A: A Small Nucleolar RNA with Potential as a Drug Target or Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including the regulation of gene expression and DNA replication. One of the most well-known snRNAs is SNORD35A, a molecule that has been identified as a potential drug target or biomarker.

SNORD35A is a 24-nt RNA molecule that contains a characteristic C/D box structure. The C/D box is a common feature of snRNAs and is responsible for maintaining the stability of the molecule. SNORD35A has a predicted localization in the nucleolus, which is the functional unit of the nuclear ribosome where protein synthesis takes place.

The discovery and characterization of SNORD35A was made by researchers at the University of California, San Diego (UCSD). The study, published in the journal RNA, identified SNORD35A as a potential drug target or biomarker in the treatment of various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD).

The authors proposed that SNORD35A could be a drug target by virtue of its unique C/D box structure and its presence in the nucleolus, which is a common site for drug targets. The authors also suggested that SNORD35A may serve as a biomarker for monitoring disease progression and response to treatment.

The potential utility of SNORD35A as a drug target is derived from its unique structure and the processes it is involved in. SNORD35A is known to play a role in the regulation of microRNA (miRNA) levels, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. The levels of miRNA in a cell can be affected by various factors, including changes in cellular stress, growth, and differentiation.

Research has shown that changes in miRNA levels can be associated with the development and progression of various diseases, including cancer, neurodegenerative diseases, and COPD. The authors of the RNA study identified SNORD35A as a potential drug target based on its miRNA-regulatory activity and its expression levels in various disease states.

In addition to its potential as a drug target, SNORD35A also has the potential as a biomarker. The authors of the RNA study proposed that SNORD35A levels may be used as a biomarker for monitoring disease progression and response to treatment in various diseases. The authors suggested that if SNORD35A levels decline in response to treatment, it may be an indication of disease progression or a failure of treatment.

The authors also suggested that SNORD35A levels may be used as a biomarker for evaluating the efficacy of different treatment approaches. By comparing the levels of SNORD35A in response to treatment with those in untreated samples, researchers may be able to determine if a particular treatment is effective in reducing SNORD35A levels and slowing disease progression.

In conclusion, SNORD35A is a small nucleolar RNA that has the potential to be a drug target or biomarker in the treatment of various diseases. The discovery and characterization of SNORD35A was made by researchers at UCSD and its unique C/D box structure and its involvement in the regulation of miRNA levels make it an attractive candidate for drug development. Further studies are needed to determine the full potential of SNORD35A as a drug target or biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 35A

The "SNORD35A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD35A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets